Mike Maloney
Director - Immunology Clasp Therapeutics
Mike joined Clasp Therapeutics in March 2023 and led the nonclinical efforts supporting the advancement of the company’s first therapeutic candidate, CLSP-1025, into clinical trials. His work focuses on translating pHLA-targeted immunotherapies from discovery through IND-enabling development. Prior to Clasp, he worked at SQZ Biotechnologies on cell-based cancer vaccines for HPV-positive solid tumors, and earlier at Abpro, where he focused on the engineering of bispecific antibodies. He earned a BS in Molecular Biology from the University of Wisconsin–Madison and a PhD in Biology from MIT.
Seminars
Thursday 25th June 2026
Standardizing Step-Up Dosing Escalation Protocols to Master Early-Phase Safety and Maximize the Therapeutic Window of T-Cell Engagers
12:00 pm
- Implementing evidence-based step-up dosing regimens to reduce the cytokine response, allowing for higher target doses while minimizing the risk of severe CRS and ICANS
- Transitioning to Modified MABEL models that utilize real-time PD markers to identify the optimal biological dose
- Ensuring escalation decisions are based on anti-tumor activity rather than just circulating drug levels
